US20150094475A1 - Preparation of Pyridonecarboxylic Acid Antibacterials - Google Patents

Preparation of Pyridonecarboxylic Acid Antibacterials Download PDF

Info

Publication number
US20150094475A1
US20150094475A1 US14/570,098 US201414570098A US2015094475A1 US 20150094475 A1 US20150094475 A1 US 20150094475A1 US 201414570098 A US201414570098 A US 201414570098A US 2015094475 A1 US2015094475 A1 US 2015094475A1
Authority
US
United States
Prior art keywords
amino
reacting
product
difluoropyridin
hours
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US14/570,098
Inventor
Anthony Haight
David M. Barnes
Geoff G.Z. Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AbbVie Inc
Original Assignee
AbbVie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AbbVie Inc filed Critical AbbVie Inc
Priority to US14/570,098 priority Critical patent/US20150094475A1/en
Publication of US20150094475A1 publication Critical patent/US20150094475A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Definitions

  • This invention pertains to processes for preparing pyridonecarboxylic acid derivatives having antibacterial properties and intermediates which are useful in the process.
  • One embodiment of this invention pertains to a process for making 2, 6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • R 1 is phenyl or naphthyl, each of which is unsubstituted or substituted with one or two independently selected —O(CH 3 ) or —O(CH 2 CH 3 ) substituents
  • R 2 is hydrogen, —CH 3 , —H 2 CH 3 , or R 1 and a phosphate base at about 50° C. to about 70° C. for a first reaction time and at about 150° C. to about 170° C. for a second reaction time, wherein the total reaction time is about 16 hours to about 24 hours, to provide a compound having formula (II)
  • Another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as described in the preceding embodiment.
  • Still another embodiment pertains to a process for making 2,6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • Still another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making 2,6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • Still another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making 2,6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • Still another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making a compound having formula (V)
  • R 4 is alkyl
  • step (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the compound having formula (V), mixing or not mixing the product mixture and water, and isolating or not isolating the compound having formula (V).
  • Still another embodiment pertains to a compound having formula (V) prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • step (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5 -trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • step (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)-amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • step (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • step (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing the product mixture and water, and isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • step (f) reacting or not reacting the product of step (e) and a base
  • step (g) reacting the product of step (f), hydrogen and a hydrogenolysis catalyst in a reaction medium consisting essentially of water, an alcohol, and an organic acid, at about 40 psi to about 60 psi and at about 50° C. to about 70° C., for about two hours to about four hours, and isolating the product,
  • step (f) is conducted.
  • Still another embodiment pertains to 3-azetidinol hydrochloride prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • step (f) reacting the product of step (e) and potassium carbonate;
  • step (g) reacting the product of step (f), hydrogen and Pd(OH) 2 on carbon in a reaction medium comprising water, an alcohol and an organic acid at about 40 psi to about 60 psi and about 50° C. to about 70° C. for about two hours to about four hours, reducing the water in the reaction medium to less than about 4 mg per mL and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • a reaction medium comprising water, an alcohol and an organic acid at about 40 psi to about 60 psi and about 50° C. to about 70° C. for about two hours to about four hours, reducing the water in the reaction medium to less than about 4 mg per mL and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • Still another embodiment pertains to 3-azetidinol hydrochloride prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • step (f) reacting the product of step (e) and potassium carbonate;
  • step (g) reacting the product of step (f), hydrogen and Pd(OH) 2 on carbon in a reaction medium comprising water, isopropanol and acetic acid at about 40 psi to about 60 psi and about 50° C. to about 70° C. for about 2 to about 4 hours, reducing the water in the reaction medium to less than about 4 mg per mL, and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • a reaction medium comprising water, isopropanol and acetic acid at about 40 psi to about 60 psi and about 50° C. to about 70° C. for about 2 to about 4 hours, reducing the water in the reaction medium to less than about 4 mg per mL, and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • Still another embodiment pertains to 3-azetidinol hydrochloride prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • step (g) reacting the product of step (f), hydrogen and Pd(OH) 2 on carbon in a reaction medium comprising water, isopropanol and acetic acid at about 40 psi and about 65° C. for about two hours, reducing the water in the reaction medium to less than about 4 mg per mL and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • a reaction medium comprising water, isopropanol and acetic acid at about 40 psi and about 65° C. for about two hours, reducing the water in the reaction medium to less than about 4 mg per mL and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • Still another embodiment pertains to 3-azetidinol hydrochloride, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making a compound having formula (VII)
  • R 5 is hydrogen or C(O)R 6 , wherein R 6 is alkyl, phenyl or naphthyl, each of which is unsubstituted or substituted with one or two or three of independently selected OCH 3 , OCH 2 CH 3 , F, Cl or Br, comprising:
  • step (i) reacting the product of step (h), 3-azetidinol hydrochloride and the bicyclic amine base and isolating or not isolating the product;
  • step (j) reacting or not reacting the product of step (i) and a OH protecting group precursor and isolating or not isolating the product.
  • Still another embodiment pertains to a compound having formula (VII), or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a compound having formula (VII), or a salt thereof, for use in preparing 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo -1,4-dihydro-3-quinolinecarboxylic acid, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxy-1-azetidinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt, ester or salt of an ester thereof.
  • Still another embodiment pertains to a compound having formula (VII), or a salt thereof.
  • Still another embodiment pertains to a compound having formula (VIIa)
  • Still another embodiment pertains to a process for making ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, comprising:
  • step (i) reacting the product of step (h), 3-azetidinol hydrochloride and a bicyclic amine base and not isolating the product;
  • step (j) reacting the product of step (i) and isobutyric anhydride and isolating or not isolating the product.
  • Still another embodiment pertains to 1-(6-amino-3,5-difluoro-2-pyridinyl)-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt thereof prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, for use in preparing 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt, ester or salt of an ester thereof.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof.
  • Still another embodiment pertains to a process for making ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, comprising:
  • step (i) reacting the product of step (h), 3-azetidinol hydrochloride and DBU and not isolating the product;
  • step (j) reacting the product of step (i) and isobutyric anhydride and isolating or not isolating the product.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1 -yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, for use in preparing 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt, ester or salt of an ester thereof.
  • Still another embodiment pertains to a process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt thereof, comprising:
  • step (l) reacting the product of step (k) and a hydroxide base
  • step (m) isolating the product of step (l).
  • Still another embodiment pertains to a compound having formula (VIII), or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a compound having formula (VIII), or a salt thereof, for use in the preparation of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof.
  • Still another embodiment pertains to a compound having formula (VIII).
  • Still another embodiment pertains to a process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, or a salt thereof, comprising:
  • step (l) reacting the product of step (k) and sodium hydroxide
  • step (m) isolating the product of step (l).
  • Still another embodiment pertains to 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid prepared as set forth in the preceding embodiment.
  • This invention pertains to pyridonecarboxylic acid derivatives having antibacterial properties and intermediates which are useful in the process.
  • Variable moieties are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
  • alkyl means C 1 -alkyl, C 2 -alkyl, C 3 -alkyl, C 4 -alkyl, C 5 -alkyl, and C 6 -alkyl.
  • C 1 -alkyl means methyl
  • C 2 -alkyl means ethyl
  • C 3 -alkyl means prop-1-yl and prop-2-yl (isopropyl).
  • C 4 -alkyl means but-1-yl, but-2-yl, 2-methylprop-1-yl, and 2-methylprop-2-yl (tert-butyl).
  • C 5 -alkyl means 2,2-dimethylprop-1-yl (neo-pentyl), 2-methylbut-1-yl, 2-methylbut-2-yl, 3-methylbut-1-yl, 3-methylbut-2-yl, pent-1-yl, pent-2-yl, and pent-3-yl.
  • C 6 -alkyl means 2,2-dimethylbut-1-yl, 2,3-dimethylbut-1-yl, 2,3-dimethylbut-2-yl, 3,3-dimethylbut-1-yl, 3,3-dimethylbut-2-yl, 2-ethylbut-1-yl, hex-1-yl, hex-2-yl, hex-3-yl, 2-methylpent-1-yl, 2-methylpent-2-yl, 2-methylpent-3-yl, 3-methylpent-1-yl, 3-methylpent-2-yl, 3-methylpent-3-yl, 4-methylpent-1-yl, and 4-methylpent-2-yl.
  • alcohol means methanol, ethanol, isopropanol, tert-butanol, and the like or a mixture thereof.
  • alkanoyl halide means a compound having formula R 6 C(O)Cl, wherein R 6 is alkyl which is unsubstituted or substituted with one or two or three of independently selected OCH 3 , OCH 2 CH 3 , F, Cl or Br.
  • aryloyl halide means a compound having formula R 6 C(O)Cl, wherein R 6 is phenyl or naphthyl, each of which is unsubstituted or substituted with one or two or three of independently selected OCH 3 , OCH 2 CH 3 , F, Cl or Br.
  • amine base means triethylamine, N-methylmorpholine, and diisopropylethylamine.
  • base means Na 2 CO 3 , NaHCO 3 , K 2 CO 3 , KHCO 3 , triethylamine, diisopropylethylamine and the like, or a mixture thereof.
  • bicyclic amine base means 1,5-diazabicyclo-[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBN).
  • carboxylic anhydride means acetic anhydride, butyric anhydride, isobutyric anhydride and the like.
  • chlorinating agent means N-chlorosuccinimide, thionyl chloride, Cl 2 , Cl 2 O and the like with or without water and with or without an acid such as sulfuric acid, phosphoric acid, trifluoroacetic acid, perchloric acid and the like.
  • hydrolysis catalyst means water-wet or not water-wet 5% palladium hydroxide, water-wet or not water-wet 10% palladium hydroxide, water-wet or not water-wet 5% palladium hydroxide on carbon, water-wet or not water-wet 10% palladium hydroxide on carbon, and the like or mixtures thereof.
  • hydroxide base means the hydroxide base of sodium, potassium, lithium, barium and the like or mixtures thereof.
  • non-protic acid means lithium chloride, magnesium chloride, zinc chloride and the like, or mixtures thereof.
  • OH protecting group precursor means a carboxylic anhydride, an alkanoyl halide, an aryloyl chloride and the like.
  • organic acid means formic acid, acetic acid, propionic acid and the like, or mixtures thereof.
  • phosphate base means K 3 PO 4 , K 2 HPO 4 , KH 2 PO 4 , Na 3 PO 4 , Na 2 HPO 4 , NaH 2 PO 4 , and the like or mixtures thereof.
  • substantially pure 3-azetidinol hydrochloride means 3-azetidinol hydrochloride having a low enough solvent content to be in powder form.
  • serialkylorthoformate means trimethylorthoformate, triethylorthoformate, triisopropylorthoformate and the like, or mixtures thereof.
  • Compounds of this invention can have one or more than one asymmetrically substituted carbon atoms in the R or S configuration.
  • Compounds having asymmetrically substituted carbon atoms enriched with one configuration over the other are assigned the configuration which is present in the higher amount, preferably 85% to 95% enrichment, more preferably 95% to 99% enrichment, and still more preferably greater than 99% enrichment.
  • compounds of this invention can exist as enantiomers, mixtures of enantiomers, diastereomers having relative stereochemistry, diastereomers having absolute stereochemistry, diastereomers having at least one asymmetrically substituted carbon atom which is enriched in one configuration and at least one asymmetrically substituted carbon atom which is not enriched, and mixtures of the preceding.
  • Compounds of this invention can also have one or more than one carbon-carbon double bond or carbon-nitrogen double bond. Accordingly, compounds of this invention can exist as geometric isomers of either Z or E configuration or as mixtures of geometric isomers.
  • Acid addition salts of compounds are prepared by reaction with acid.
  • acid addition salts of compounds are prepared by reaction with acid.
  • acid for example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, citrate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate,
  • Base addition salts of compounds of this invention may be prepared by reaction with a base such as the hydroxide, carbonate, bicarbonate, phosphate, hydrogen phosphate, or dihydrogen phosphate of cations such as calcium, iron, lithium, potassium, sodium or magnesium.
  • a base such as the hydroxide, carbonate, bicarbonate, phosphate, hydrogen phosphate, or dihydrogen phosphate of cations such as calcium, iron, lithium, potassium, sodium or magnesium.
  • the filtrant was mixed with sodium bicarbonate (104Kg) in acetonitrile (1110Kg), and the mixture was azeotropically distilled with acetonitrile addition to maintain a volume of 900L, diluted with acetonitrile (400L), stirred at 75° C.
  • the orgainc layer was isolated and concentrated with an isopropanol azeotrope.
  • the concentrate was mixed with acetic acid (25.8Kg), added to half-wet 5% palladium hydroxide on carbon (13.1Kg), stirred at 55-65° C.
  • a suspension of benzylamine (106Kg) and milled (20 mesh) potassium phosphate (45Kg) in N-methylpyrrolidinone (100Kg) at 50° C. was treated with 2,3,5,6-tetrafluoropyridine (30Kg), stirred for 30 minutes at 50-70° C. and at 165° C. for 12-18 hours, cooled to 10° C., treated sequentially with water (240L) and 50% (v/v) isopropyl acetate/heptane (240L), isopropyl acetate (37.9 Kg), and water (88.5 Kg), each at 10° C.
  • the filtrate was washed twice with 6% citric acid solution having its pH adjusted to 4 with potassium hydroxide (water (200Kg)/citric acid (l2Kg)/potassium hydroxide (2Kg)), 1M sodium bicarbonate solution (150Kg) and water (150Kg) and concentrated.
  • the concentrate was treated with heptane(1005Kg) over 90 minutes, and the solution was cooled to 0° C. and filtered.
  • the filtrant was washed with heptane (220Kg) and dried under vacuum at 40° C. to provide 61.5Kg of product, which was stored in an opaque container under nitrogen.
  • 1 H NMR (CDCl 3 , 300 MHz) ⁇ 7.03 (t, 1H), 4.5-4.0 (brs, 4H).
  • a suspension of potassium ethyl malonate (50.8Kg) and magnesium chloride (34.5Kg) in toluene (130Kg) below 0° C. was treated with THF (265L), cooled to 0° C., treated with triethylamine (75Kg), warmed to 50° C., stirred for 1-5 hours, cooled to 0° C., treated with 22% (w/w) of EXAMPLE 5 in toluene (163Kg), warmed to ambient temperature, stirred for 2 hours, added to 2M HCl (407Kg), stirred for 30 minutes, separated from the water layer and washed with water.
  • EXAMPLE 7A The solution of EXAMPLE 7A was treated with N-methylpyrrolidinone (210Kg), acetonitrile (161Kg) and water (3Kg), added to a suspension of EXAMPLE 4 (57.4Kg) in 1:1 N-methylpyrrolidinone (210Kg) and acetonitrile (161Kg), stirred for 2 hours, added to water (662Kg) and filtered. The filtrant was washed with (2:1) acetonitrile/water and water and dried under vacuum at 60° C. to provide 119.5Kg of product.
  • EXAMPLE 8A below 40° C. was treated with EXAMPLE 2 (33.9Kg) and DBU (109Kg) and stirred for 2-5 hours to provide a solution of EXAMPLE 8B that was used immediately.
  • EXAMPLE 8B The solution of EXAMPLE 8B was treated with isobutyric anhydride (99.7Kg), stirred at 35° C. for 1-2 hours, cooled to 20-30° C., treated with ethyl acetate (104Kg) and 10% aqueous citric acid (570Kg) and filtered. The filtrant was washed with water and dried under vacuum at 50° C. to provide 136Kg of product.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Agronomy & Crop Science (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dentistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, and therapeutically acceptable salts thereof, and intermediates used in the process are disclosed.

Description

    CROSS-REFERENCE TO RELATED APPLICATIONS
  • This application is a continuation of and claims the benefit of priority of U.S. patent application Ser. No. 14/176,334, filed Feb. 10, 2014, which is a continuation of and claims the benefit of priority of U.S. patent application Ser. No. 13/663,601, filed Oct. 30, 2012, now U.S. Pat. No. 8,648,196, which is a continuation of and claims the benefit of priority of U.S. patent application Ser. No. 12/543,240, filed Aug. 18, 2009, now U.S. Pat. No. 8,299,254, which is a continuation of and claims the benefit of priority of U.S. patent application Ser. No. 11/191,319, filed Jul. 28, 2005, now U.S. Pat. No. 7,576,216, which claims priority to U.S. Provisional Patent Application No. 60/617,327, filed Oct. 8, 2004 and U.S. Provisional Patent Application No. 60/592,893, filed Jul. 30, 2004, the entire disclosures of which are incorporated by reference herein.
    • FIELD OF THE INVENTION
  • This invention pertains to processes for preparing pyridonecarboxylic acid derivatives having antibacterial properties and intermediates which are useful in the process.
    • BACKGROUND OF THE INVENTION
  • Many compounds having a pyridonecarboxylic acid moiety re known to be useful as antibacterials. For example, a series of novel quinolone antibacterials appears in PCT Application No. PCT/JP96/02710, published as WO97/11068 on Mar. 27, 1997 and issued in United States as U.S. Pat. No. 5,998,436 on Dec. 7, 1999, U.S. Pat. No. 6,133,284 on Oct. 17, 2000, and U.S. Pat. No. 6,156,903 on Dec. 5, 2000.
  • There is therefore an existing need for processes for making these compounds in large scale quantities.
    • SUMMARY OF THE INVENTION
  • One embodiment of this invention, therefore, pertains to a process for making 2, 6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • (a) reacting 2,3,5,6-tetrafluoropyridine, a compound having formula (I)

  • H2NCH(R1)(R2)  (I),
  • or a salt thereof, wherein R1 is phenyl or naphthyl, each of which is unsubstituted or substituted with one or two independently selected —O(CH3) or —O(CH2CH3) substituents, and R2 is hydrogen, —CH3, —H2CH3, or R1 and a phosphate base at about 50° C. to about 70° C. for a first reaction time and at about 150° C. to about 170° C. for a second reaction time, wherein the total reaction time is about 16 hours to about 24 hours, to provide a compound having formula (II)
  • Figure US20150094475A1-20150402-C00001
  • and isolating or not isolating the compound having formula (II);
  • (b) reacting, for about 45 minutes to about 2 hours, the compound having formula (II), hydrogen and a hydrogenolysis catalyst in water and a co-solvent, wherein the water is present in about 0.1 to about 6 molar equivalents per molar equivalent of the compound having formula (II).
  • Another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as described in the preceding embodiment.
  • Still another embodiment pertains to a process for making 2,6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • (a) reacting 2,3,5,6-tetrafluoropyridine, benzylamine and a phosphate base at about 50° C. to about 70° C. for a first reaction time and at about 150° C. to about 170° C. for a second reaction time, wherein the total reaction time is about 16 hours to about 24 hours, to provide N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine;
  • (b) reacting, for about 45 minutes to about 2 hours, the N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine, hydrogen and a hydrogenolysis catalyst in water and a co-solvent, wherein the water is present in about 0.1 to about 6 molar equivalents per molar equivalent of the N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine.
  • Still another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making 2,6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • (a) reacting 2,3,5,6-tetrafluoropyridine, benzylamine and a plurality of potassium phosphate particles having a mean diameter of about 420 micrometers (40 mesh) to about 2000 micrometers (10 mesh) at about 50° C. to about 70° C. for a first reaction time and at about 150° C. to about 170° C. for a second reaction time, wherein the total reaction time is about 16 hours to about 24 hours, to provide N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine;
  • (b) reacting for about 45 minutes to about 2 hours the N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine, formic acid and 20% palladium on carbon in water and a co-solvent, wherein the water is present in about 0.1 to about 6 molar equivalents per molar equivalent of the N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine.
  • Still another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making 2,6-diamino-3,5-difluoropyridine, or a salt thereof, comprising:
  • (a) reacting 2,3,5,6-tetrafluoropyridine, benzylamine and a plurality of potassium phosphate particles having a mean diameter of about 420 micrometers (40 mesh) to about 2000 micrometers (10 mesh) at about 50° C. to about 70° C. for about 15 minutes to about 5 hours and at about 150° C. to about 170° C. for about 10 hours to about 20 hours to provide N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine.
  • (b) reacting, for about 45 minutes to about 2 hours, the N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine, formic acid and 20% palladium on carbon in water and isopropyl acetate, wherein the water is present in about 1 to about 5 molar equivalents per molar equivalent of the N2,N6-dibenzyl-2,6-diamino-3,5-difluoropyridine.
  • Still another embodiment pertains to 2,6-diamino-3,5-difluoropyridine, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making a compound having formula (V)
  • Figure US20150094475A1-20150402-C00002
  • or a salt thereof, wherein R4 is alkyl, comprising:
  • (c) reacting, at about 100° C. to about 140° C., a compound having formula (IV)
  • Figure US20150094475A1-20150402-C00003
  • and a trialkylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and a carboxylic anhydride for about 30 minutes to about 12 hours; and
  • (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the compound having formula (V), mixing or not mixing the product mixture and water, and isolating or not isolating the compound having formula (V).
  • Still another embodiment pertains to a compound having formula (V) prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • (c) reacting, at about 100° C. to about 140° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and a trialkylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and a carboxylic anhydride for about 30 minutes to about 12 hours; and
  • (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5 -trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • (c) reacting, at about 100° C. to about 140° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and triethylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and acetic anhydride for about 30 minutes to about 12 hours; and
  • (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)-amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • (c) reacting, at about 110° C. to about 115° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and triethylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and acetic anhydride for about 30 minutes to about 12 hours; and
  • (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
  • (c) reacting, at about 110° C. to about 115° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and triethylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and acetic anhydride for about 30 minutes to about 12 hours; and
  • (d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing the product mixture and water, and isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
  • Still another embodiment pertains to (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • (e) reacting (±)-2-(chloromethyl)oxirane, sodium bicarbonate and the compound having formula (I) to provide a compound having formula (VI),
  • Figure US20150094475A1-20150402-C00004
  • reacting the compound having formula (VI) and either hydrogen chloride at about −10° C. to about 0° C. or (2E/Z)-2-butenedioic (maleic) acid at about 35° C. to about 45° C., and isolating either the hydrochloride salt or the maleate acid salt, respectively, of the compound having formula (VI);
  • (f) reacting or not reacting the product of step (e) and a base; and
  • (g) reacting the product of step (f), hydrogen and a hydrogenolysis catalyst in a reaction medium consisting essentially of water, an alcohol, and an organic acid, at about 40 psi to about 60 psi and at about 50° C. to about 70° C., for about two hours to about four hours, and isolating the product,
  • with the proviso that when the product of step (e) is the maleate salt, step (f) is conducted.
  • Still another embodiment pertains to 3-azetidinol hydrochloride prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • (e) reacting (±)-2-(chloromethyl)oxirane, sodium bicarbonate and benzylamine to provide 1-benzyl-3-azetidinol, reacting the 1-benzyl-3-azetidinol and (2E/Z)-2-butenedioic acid at about 35° C. to about 45° C., and isolating 1-benzyl-3-azetidinol (2E/Z)-2-butenedioate;
  • (f) reacting the product of step (e) and potassium carbonate; and
  • (g) reacting the product of step (f), hydrogen and Pd(OH)2 on carbon in a reaction medium comprising water, an alcohol and an organic acid at about 40 psi to about 60 psi and about 50° C. to about 70° C. for about two hours to about four hours, reducing the water in the reaction medium to less than about 4 mg per mL and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • Still another embodiment pertains to 3-azetidinol hydrochloride prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • (e) reacting (±)-2-(chloromethyl)oxirane, sodium bicarbonate and benzylamine in acetonitrile and water to provide 1-benzyl-3-azetidinol, reacting the 1-benzyl-3-azetidinol and (2E/Z)-2-butenedioic acid at about 35° C. to about 45° C., and isolating 1-benzyl-3-azetidinol (2E/Z)-2-butenedioate;
  • (f) reacting the product of step (e) and potassium carbonate; and
  • (g) reacting the product of step (f), hydrogen and Pd(OH)2 on carbon in a reaction medium comprising water, isopropanol and acetic acid at about 40 psi to about 60 psi and about 50° C. to about 70° C. for about 2 to about 4 hours, reducing the water in the reaction medium to less than about 4 mg per mL, and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • Still another embodiment pertains to 3-azetidinol hydrochloride prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making substantially pure 3-azetidinol hydrochloride comprising:
  • (e) reacting (±)-2-(chloromethyl)oxirane, sodium bicarbonate and benzylamine at about 0° C. to about 80° C. in acetonitrile and water to provide 1-benzyl-3-azetidinol, reacting the 1-benzyl-3-azetidinol and (2E/Z)-2-butenedioic acid at about 40° C., and isolating 1 -benzyl-3-azetidinol (2E/Z)-2-butenedioate;
  • (f) reacting the 1-benzyl-3-azetidinol (2E/Z)-2-butenedioate and potassium carbonate; and
  • (g) reacting the product of step (f), hydrogen and Pd(OH)2 on carbon in a reaction medium comprising water, isopropanol and acetic acid at about 40 psi and about 65° C. for about two hours, reducing the water in the reaction medium to less than about 4 mg per mL and treating the reaction medium first with hydrogen chloride gas between about 0° C. and about 20° C. and then with toluene at about 40° C.
  • Still another embodiment pertains to 3-azetidinol hydrochloride, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making a compound having formula (VII)
  • Figure US20150094475A1-20150402-C00005
  • or a salt thereof,
  • wherein R5 is hydrogen or C(O)R6, wherein R6 is alkyl, phenyl or naphthyl, each of which is unsubstituted or substituted with one or two or three of independently selected OCH3, OCH2CH3, F, Cl or Br, comprising:
  • (h) reacting the compound having formula (V) or a salt thereof, a non-protic acid and a bicyclic amine base;
  • (i) reacting the product of step (h), 3-azetidinol hydrochloride and the bicyclic amine base and isolating or not isolating the product; and
  • (j) reacting or not reacting the product of step (i) and a OH protecting group precursor and isolating or not isolating the product.
  • Still another embodiment pertains to a compound having formula (VII), or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a compound having formula (VII), or a salt thereof, for use in preparing 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo -1,4-dihydro-3-quinolinecarboxylic acid, 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxy-1-azetidinyl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt, ester or salt of an ester thereof.
  • Still another embodiment pertains to a compound having formula (VII), or a salt thereof.
  • Still another embodiment pertains to a compound having formula (VIIa)
  • Figure US20150094475A1-20150402-C00006
  • prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a process for making ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, comprising:
  • (h) reacting ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, a non-protic acid and a bicyclic amine base and not isolating or isolating the product;
  • (i) reacting the product of step (h), 3-azetidinol hydrochloride and a bicyclic amine base and not isolating the product; and
  • (j) reacting the product of step (i) and isobutyric anhydride and isolating or not isolating the product.
  • Still another embodiment pertains to 1-(6-amino-3,5-difluoro-2-pyridinyl)-6,7-difluoro-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt thereof prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, for use in preparing 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt, ester or salt of an ester thereof.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof.
  • Still another embodiment pertains to a process for making ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, comprising:
  • (h) reacting ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, lithium chloride and DBU and not isolating the product;
  • (i) reacting the product of step (h), 3-azetidinol hydrochloride and DBU and not isolating the product; and
  • (j) reacting the product of step (i) and isobutyric anhydride and isolating or not isolating the product.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1 -yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate, or a salt thereof, for use in preparing 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt, ester or salt of an ester thereof.
  • Still another embodiment pertains to a process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid, or a salt thereof, comprising:
  • (k) reacting the compound having formula (VII), or a salt thereof, and a chlorinating agent and isolating or not isolating a compound having formula (VIII)
  • Figure US20150094475A1-20150402-C00007
  • (l) reacting the product of step (k) and a hydroxide base; and
  • (m) isolating the product of step (l).
  • Still another embodiment pertains to a compound having formula (VIII), or a salt thereof, prepared as set forth in the preceding embodiment.
  • Still another embodiment pertains to a compound having formula (VIII), or a salt thereof, for use in the preparation of 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid or a salt thereof.
  • Still another embodiment pertains to a compound having formula (VIII).
  • Still another embodiment pertains to a process for making 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid, or a salt thereof, comprising:
  • (k) reacting ethyl 1-(6-amino-3,5-difluoropyridin-2-yl)-6-fluoro-7-(3-(isobutyryloxy)azetidin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylate or a salt thereof and N-chlorosuccinimide and isolating or not isolating the product;
  • (l) reacting the product of step (k) and sodium hydroxide; and
  • (m) isolating the product of step (l).
  • Still another embodiment pertains to 1-(6-amino-3,5-difluoropyridin-2-yl)-8-chloro-6-fluoro-7-(3-hydroxyazetidin-1-yl)-4-oxo-1,4-dihydro-3-quinolinecarboxylic acid prepared as set forth in the preceding embodiment.
    • DETAILED DESCRIPTION OF THE INVENTION
  • This invention pertains to pyridonecarboxylic acid derivatives having antibacterial properties and intermediates which are useful in the process.
  • Variable moieties are represented by identifiers (capital letters with numerical and/or alphabetical superscripts) and may be specifically embodied.
  • The term “alkyl,” as used herein, means C1-alkyl, C2-alkyl, C3-alkyl, C4-alkyl, C5-alkyl, and C6-alkyl.
  • The term “C1-alkyl,” as used herein, means methyl.
  • The term “C2-alkyl,” as used herein, means ethyl.
  • The term “C3-alkyl,” as used herein, means prop-1-yl and prop-2-yl (isopropyl).
  • The term “C4-alkyl,” as used herein, means but-1-yl, but-2-yl, 2-methylprop-1-yl, and 2-methylprop-2-yl (tert-butyl).
  • The term “C5-alkyl,” as used herein, means 2,2-dimethylprop-1-yl (neo-pentyl), 2-methylbut-1-yl, 2-methylbut-2-yl, 3-methylbut-1-yl, 3-methylbut-2-yl, pent-1-yl, pent-2-yl, and pent-3-yl.
  • The term “C6-alkyl,” as used herein, means 2,2-dimethylbut-1-yl, 2,3-dimethylbut-1-yl, 2,3-dimethylbut-2-yl, 3,3-dimethylbut-1-yl, 3,3-dimethylbut-2-yl, 2-ethylbut-1-yl, hex-1-yl, hex-2-yl, hex-3-yl, 2-methylpent-1-yl, 2-methylpent-2-yl, 2-methylpent-3-yl, 3-methylpent-1-yl, 3-methylpent-2-yl, 3-methylpent-3-yl, 4-methylpent-1-yl, and 4-methylpent-2-yl.
  • The term “alcohol,” as used herein, means methanol, ethanol, isopropanol, tert-butanol, and the like or a mixture thereof.
  • The term “alkanoyl halide,” as used herein, means a compound having formula R6C(O)Cl, wherein R6 is alkyl which is unsubstituted or substituted with one or two or three of independently selected OCH3, OCH2CH3, F, Cl or Br.
  • The term “aryloyl halide,” as used herein, means a compound having formula R6C(O)Cl, wherein R6 is phenyl or naphthyl, each of which is unsubstituted or substituted with one or two or three of independently selected OCH3, OCH2CH3, F, Cl or Br.
  • The effect of the solubility of compounds having formula (VII), wherein R4 is ethyl and R6 is variable, in ethyl acetate, is shown in
  • TABLE 1
    R6 solubility (mg/mL)
    CH3 1.7
    CH2CH3 0.2
    CH(CH3)2 6.4
    phenyl 0.2
  • The term “amine base,” as used herein, means triethylamine, N-methylmorpholine, and diisopropylethylamine.
  • The term “base,” as used herein, means Na2CO3, NaHCO3, K2CO3, KHCO3, triethylamine, diisopropylethylamine and the like, or a mixture thereof.
  • The term “bicyclic amine base,” as used herein, means 1,5-diazabicyclo-[4.3.0]non-5-ene (DBN) and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBN).
  • The term “carboxylic anhydride,” as used herein, means acetic anhydride, butyric anhydride, isobutyric anhydride and the like.
  • The term “chlorinating agent,” as used herein, means N-chlorosuccinimide, thionyl chloride, Cl2, Cl2O and the like with or without water and with or without an acid such as sulfuric acid, phosphoric acid, trifluoroacetic acid, perchloric acid and the like.
  • The yields of chlorinations of compounds having formula (VII), wherein R4 is CH2CH3 and R5 is C(O)R6, wherein R6 is CH(CH3)2, with N-chlorosuccinimide in ethyl acetate is shown in
  • TABLE 2
    acid/additive amount (equivalents) yield (%)
    TFA/water 0.1-0.2 83
    HClO4 0.1-0.2 95
    H3PO4 0.1 90
    H2SO4 0.065 90
  • The term “hydrogenolysis catalyst,” as used herein, means water-wet or not water-wet 5% palladium hydroxide, water-wet or not water-wet 10% palladium hydroxide, water-wet or not water-wet 5% palladium hydroxide on carbon, water-wet or not water-wet 10% palladium hydroxide on carbon, and the like or mixtures thereof.
  • The term “hydroxide base,” as used herein, means the hydroxide base of sodium, potassium, lithium, barium and the like or mixtures thereof.
  • The term “non-protic acid,” as used herein, means lithium chloride, magnesium chloride, zinc chloride and the like, or mixtures thereof.
  • The term “OH protecting group precursor,” as used herein, means a carboxylic anhydride, an alkanoyl halide, an aryloyl chloride and the like.
  • The term “organic acid,” as used herein, means formic acid, acetic acid, propionic acid and the like, or mixtures thereof.
  • The term “phosphate base,” as used herein, means K3PO4, K2HPO4, KH2PO4, Na3PO4, Na2HPO4, NaH2PO4, and the like or mixtures thereof.
  • The term “substantially pure 3-azetidinol hydrochloride,” as used herein, means 3-azetidinol hydrochloride having a low enough solvent content to be in powder form.
  • The term “trialkylorthoformate” means trimethylorthoformate, triethylorthoformate, triisopropylorthoformate and the like, or mixtures thereof.
  • Compounds of this invention can have one or more than one asymmetrically substituted carbon atoms in the R or S configuration. Compounds having asymmetrically substituted carbon atoms enriched with one configuration over the other are assigned the configuration which is present in the higher amount, preferably 85% to 95% enrichment, more preferably 95% to 99% enrichment, and still more preferably greater than 99% enrichment. Accordingly, compounds of this invention can exist as enantiomers, mixtures of enantiomers, diastereomers having relative stereochemistry, diastereomers having absolute stereochemistry, diastereomers having at least one asymmetrically substituted carbon atom which is enriched in one configuration and at least one asymmetrically substituted carbon atom which is not enriched, and mixtures of the preceding.
  • Compounds of this invention can also have one or more than one carbon-carbon double bond or carbon-nitrogen double bond. Accordingly, compounds of this invention can exist as geometric isomers of either Z or E configuration or as mixtures of geometric isomers.
  • The terms “R”, “S”, “Z”, and “E” are as defined by the IUPAC 1974 Recommendations for Section E, Fundamental Stereochemistry, Pure Appl. Chem. (1976) 45, 13-10.
  • Compounds of this invention may exist as acid addition salts or base addition salts and may be prepared during their isolation or following their purification. Acid addition salts of compounds are prepared by reaction with acid. For example, the acetate, adipate, alginate, bicarbonate, citrate, aspartate, benzoate, benzenesulfonate, bisulfate, butyrate, camphorate, camphorsufonate, citrate, digluconate, formate, fumarate, glycerophosphate, glutamate, hemisulfate, heptanoate, hexanoate, hydrochloride, hydrobromide, hydroiodide, lactobionate, lactate, maleate, mesitylenesulfonate, methanesulfonate, naphthylenesulfonate, nicotinate, oxalate, pamoate, pectinate, persulfate, phosphate, picrate, propionate, succinate, tartrate, thiocyanate, trichloroacetate, trifluoroacetate, para-toluenesulfonate, and undecanoate salts of compounds of this invention are meant to be embraced thereby. Base addition salts of compounds of this invention may be prepared by reaction with a base such as the hydroxide, carbonate, bicarbonate, phosphate, hydrogen phosphate, or dihydrogen phosphate of cations such as calcium, iron, lithium, potassium, sodium or magnesium.
  • The following examples are meant to further embody the compounds and processes of this invention.
    • EXAMPLE 1
  • A solution of benzylamine (73Kg) in water (650.4Kg) at 0° C. was treated with epichlorohydrin (61Kg), stirred for approximately 2 hours until solid formed, stored at 10° C. for 16 hours, and filtered. The filtrant was mixed with sodium bicarbonate (104Kg) in acetonitrile (1110Kg), and the mixture was azeotropically distilled with acetonitrile addition to maintain a volume of 900L, diluted with acetonitrile (400L), stirred at 75° C. for 10-16 hours, cooled to ambient temperature, filtered through diatomaceous earth (Celite®), concentrated to 300L, added over 1 hour to a solution of maleic acid (52.8Kg) in acetonitrile (310Kg) at 40° C., cooled to 0° C., and filtered. The filtrant was washed with isopropyl acetate and dried to provide 113.6Kg of product. Mp 127-129° C.; 1H NMR (CD3OD) δ 7.54-7.51 (m, 5H), 6.33 (s, 2H), 4.98 (brs, 4H, exchangeable), 4.72 (quintet, J=6 Hz, 1H), 4.45 (s, 2H), 4.39 (m, 2H), 4.01 (m, 2H), 3.38 (CHD2OD).
    • EXAMPLE 2
  • A suspension of EXAMPLE 1 (111.6Kg) in ethyl acetate (605Kg) was treated with 25% aqueous potassium carbonate (560Kg) until the suspension homogenized. The orgainc layer was isolated and concentrated with an isopropanol azeotrope. The concentrate was mixed with acetic acid (25.8Kg), added to half-wet 5% palladium hydroxide on carbon (13.1Kg), stirred at 55-65° C. under hydrogen at 40 psi for 2-8 hours, cooled to ambient temperature, filtered, washed with isopropanol, concentrated with an isopropanol azeotrope to 110L, cooled to 5-10° C., treated with HC1 gas (14Kg), stirred at ambient temperature for 1 hour and at 40° C. for 30 minutes, treated with toluene (210Kg) over 1 hour, stirred for 30 minutes, cooled to ambient temperature, and filtered. The filtrant was washed with toluene and dried under vacuum at 50° C. to provide 36.7Kg of product. 1H NMR (CD3OD) δ 4.57 (m, 1H), 4.08 (m, 2H), 3.80 (m, 2H), 3.38 (CHD2OD).
    • EXAMPLE 3
  • A suspension of benzylamine (106Kg) and milled (20 mesh) potassium phosphate (45Kg) in N-methylpyrrolidinone (100Kg) at 50° C. was treated with 2,3,5,6-tetrafluoropyridine (30Kg), stirred for 30 minutes at 50-70° C. and at 165° C. for 12-18 hours, cooled to 10° C., treated sequentially with water (240L) and 50% (v/v) isopropyl acetate/heptane (240L), isopropyl acetate (37.9 Kg), and water (88.5 Kg), each at 10° C. The bottom and middle layers were separated and washed with 2M HCl (120L) and water (120L), each precooled to 10° C., and concentrated. The concentrate was treated with isopropyl acetate (275Kg) and stored in an opaque container under nitrogen. 1H NMR (CDCl3, 300 MHz) δ 7.29-7.24 (m, 10H), 6.97 (t, 1H), 4.57 (s, 4H).
    • EXAMPLE 4
  • A mixture of half-wet 20% palladium hydroxide on carbon (68.1Kg) was treated sequentially with 39.1% (w/w) EXAMPLE 3 in isopropyl acetate (410Kg total, 160Kg EXAMPLE 3), isopropyl acetate (550Kg) and 88% formic acid (57Kg). The mixture was stirred at 50° C. for 2 hours and filtered under nitrogen through diatomaceous earth (Celite®) with isopropyl acetate (200Kg) rinsing. The filtrate was washed twice with 6% citric acid solution having its pH adjusted to 4 with potassium hydroxide (water (200Kg)/citric acid (l2Kg)/potassium hydroxide (2Kg)), 1M sodium bicarbonate solution (150Kg) and water (150Kg) and concentrated. The concentrate was treated with heptane(1005Kg) over 90 minutes, and the solution was cooled to 0° C. and filtered. The filtrant was washed with heptane (220Kg) and dried under vacuum at 40° C. to provide 61.5Kg of product, which was stored in an opaque container under nitrogen. 1H NMR (CDCl3, 300 MHz) δ 7.03 (t, 1H), 4.5-4.0 (brs, 4H).
    • EXAMPLE 5
  • A solution of 2,4,5-trifluorobenzoic acid (139.5Kg) in DMF (8.4Kg) and toluene (613Kg) was treated with thionyl chloride (139.4Kg), stirred at 60° C. for 3.5 hours, cooled to 25° C., concentrated to 20% of its original volume, treated with toluene (600Kg), distilled and stored at ambient temperature.
    • EXAMPLE 6
  • A suspension of potassium ethyl malonate (50.8Kg) and magnesium chloride (34.5Kg) in toluene (130Kg) below 0° C. was treated with THF (265L), cooled to 0° C., treated with triethylamine (75Kg), warmed to 50° C., stirred for 1-5 hours, cooled to 0° C., treated with 22% (w/w) of EXAMPLE 5 in toluene (163Kg), warmed to ambient temperature, stirred for 2 hours, added to 2M HCl (407Kg), stirred for 30 minutes, separated from the water layer and washed with water. This procedure was repeated, and the organic layers were combined, concentrated with an ethanol (150L) azeotrope, treated with water (30% by weight of the organic layer), stirred for 3 hours at 0° C., and filtered. The filtrant was washed with 3:1 ethanol/water and dried under vacuum at 35-45° C. to provide 86Kg of product. 1H NMR (CDCl3) (keto) δ 7.75 (ddd, J=10.8, 10.8, 6.0 Hz, 1H), 7.02 (ddd, 1H), 4.27 (q, J=7.2 Hz, 2H), 3.95 (d, 4.2Hz, 2H), 1.35 (t, J=7.3 Hz, 3H); (enol) δ 12.72 (s, 1H), 7.85 (ddd, J=10.5, 9.6, 6.6 Hz, 1H), 6.96 (ddd, J=10.5, 10.5, 6.6 Hz, 1H), 5.84 (s, 1H), 4.23 (q, J=7.2 Hz, 2H), 1.27 (t, J=7.4 Hz, 3H).
    • EXAMPLE 7A
  • A solution of EXAMPLE 6 (83.2Kg) in triethyl orthoformate (80.1Kg) at reflux was stirred for 0.5-1 hour, treated with acetic anhydride (103.5Kg), stirred for 12 hours and cooled to ambient temperature to provide a solution that was used immediately.
    • EXAMPLE 7B
  • The solution of EXAMPLE 7A was treated with N-methylpyrrolidinone (210Kg), acetonitrile (161Kg) and water (3Kg), added to a suspension of EXAMPLE 4 (57.4Kg) in 1:1 N-methylpyrrolidinone (210Kg) and acetonitrile (161Kg), stirred for 2 hours, added to water (662Kg) and filtered. The filtrant was washed with (2:1) acetonitrile/water and water and dried under vacuum at 60° C. to provide 119.5Kg of product. Mp 157-160° C.; 1H NMR (CDCl3, 300 MHz) (E) δ 1.15 (t, 3H), 4.16 (q, 2H), 4.64 (br s, 2H), 6.90 (m, 1H), 7.22 (t, 1H), 7.32 (m, 1H), 9.03 (d, 1H), 12.44 (bd, 1H); (Z) δ 1.03 (t, 3H), 4.11 (q, 2H), 4.60 (br s, 2H), 6.90 (m, 1H), 7.20 (t, 1H), 7.48 (m, 1H), 8.90 (d, 1H), 11.17 (bd, 1H).
    • EXAMPLE 8A
  • A mixture of EXAMPLE 7 (115Kg) and lithium chloride (24.3Kg) in N-methylpyrrolidinone (769Kg) below 35° C. was treated with DBU (946.1Kg) and stirred for 2 hours to provide a solution of EXAMPLE 8A that was used immediately.
    • EXAMPLE 8B
  • The solution of EXAMPLE 8A below 40° C. was treated with EXAMPLE 2 (33.9Kg) and DBU (109Kg) and stirred for 2-5 hours to provide a solution of EXAMPLE 8B that was used immediately.
    • EXAMPLE 8C
  • The solution of EXAMPLE 8B was treated with isobutyric anhydride (99.7Kg), stirred at 35° C. for 1-2 hours, cooled to 20-30° C., treated with ethyl acetate (104Kg) and 10% aqueous citric acid (570Kg) and filtered. The filtrant was washed with water and dried under vacuum at 50° C. to provide 136Kg of product. 1H NMR (DMSO-d6, 400 MHz) δ 8.49 (s, 1H), 8.00 (dd, J=9.0, 9.3 Hz, 1H), 7.75 (d, J=12.8 Hz, 1H), 6.79 (br s, 2H), 5.95 (dd, J=1.5, 7.6 Hz, 1H), 5.21 (m, 1H), 4.36 (t, J=7.4 Hz, 2H), 4.02 (q, J=7.0 Hz, 2H), 3.95 (dd, J=3.7, 9.2 Hz, 2H), 2.58 (hept, J=7.0 Hz, 1H), 1.26 (t, J=7.0 Hz, 3H), 1.11 (d, J=7.0 Hz, 6H).
    • EXAMPLE 9A
  • A suspension of EXAMPLE 8C (99.8Kg) in dichloromethane (813Kg) at 0-5° C. was treated with 1,3-dichloro-5,5-dimethylhydantoin (39.5Kg) in dichloromethane (540Kg) over 2 hours then with 10% aqueous sodium bisulfite (550Kg), separated from the water layer, washed with 5% sodium bicarbonate and water and concentrated. The concentrate was dissolved in methyl tert-butyl ether, crystallized at 5° C. and dried at 65° C. to provide 109 Kg of product as the methyl tert-butyl ether solvate. 1H NMR (CDCl3) methyl tert-butyl ether solvate: δ 8.35 (s, 1H), 7.95 (d, J=14.7 Hz, 1H), 7.24 (t, J=8.9 Hz, 1H), 5.19-5.11 (m, 1H), 4.82-4.72 (m, 2H), 4.39-4.27 (m, 2H), 4.35 (q, J=7.5Hz, 2H), 3.19 (s, 3H), 2.57 (sept, J=7.1 Hz, 1H), 1.36 (t, J=7.4 Hz, 3H), 1.17 (d, J=7.1 Hz, 6H), 1.18 (s, 9H).
    • EXAMPLE 9B
  • A suspension of EXAMPLE 8C (110Kg) and N-chlorosuccinimide (31Kg) in ethyl acetate (785Kg) at 0-5° C. was treated with phosphoric acid (2.5Kg) and water (1Kg) while the temperature was kept at less than 5° C., warmed to 22° C., stirred for 3 hours, washed with sodium bicarbonate solution and 10% sodium sulfite solution and concentrated. The concentrate was treated with methyl tert-butyl ether (403Kg), and the slurry was stirred at 35° C. for 30 minutes, cooled to 5° C. and filtered.
    • EXAMPLE 9C
  • A suspension of EXAMPLE 8C (4.91 g) and N-chlorosuccinimide (1.36 g) in ethyl acetate (500 mL) was treated with trifluoroacetic acid (0.15 mL) over 3 hours then with 5% aqueous sodium bicarbonate (25 mL), separated from the water layer, washed with 10% aqueous sodium hydrogen sulfate (10 mL) and concentrated to 50 mL with a methyl tert-butyl ether (250 mL) azeotrope. The concentrate was dissolved in methyl tert-butyl ether, and the solution was stirred at 45° C. until solid formed, cooled to ambient temperature, and filtered. The filtrant was washed with methyl tert-butyl ether and dried under vacuum at 50° C. to provide 5.33 g of product as the methyl tert-butyl ether solvate. 1H NMR(CDCl3) δ 8.35 (s, 1H), 7.95 (d, J=14.7Hz, 1H), 7.24 (t, J=8.9Hz, 1H), 5.19-5.11 (m, 1H), 4.82-4.72 (m, 2H), 4.39-4.27 (m, 2H), 4.35 (q, J=7.5 Hz, 2H), 3.19 (s, 3H), 2.57 (sept, J=7.1 Hz, 1H), 1.36 (t, J=7.4Hz, 3H), 1.17 (d, J=7.lHz, 6H), 1.18 (s, 9H).
    • EXAMPLE 10
  • A solution of N-chlorosuccinimide (25.3Kg) in methyl acetate (419Kg) at 17° C. was treated with sulfuric acid (560 g), transferred to a slurry of EXAMPLE 8C (92.7Kg) in ethyl acetate (244Kg) at 17° C. while maintaining the reaction temperature at 17° C., quenched/washed with 1.5% aqueous sodium bicarbonate (370Kg), washed with 10% aqueous sodium sulfite (200Kg) and concentrated. The concentrate was dissolved in isopropanol, treated with 4% (w/w) aqueous potassium hydroxide (750Kg), stirred at 50° C. until hydrolysis was complete, passed through a polishing filter, treated with 12% aqueous acetic acid (410Kg) and filtered. The filtrant was washed with water and dried at 50° C. to provide 73Kg of product. 1H NMR (CDCl3) 6 14.63 (brs, 1H), 8.70 (d, J=0.7 Hz, 1H), 7.95 (dd, J=9.9, 0.7 Hz, 1H), 7.83 (d, J=13.6 Hz, 1H), 6.75 (s, 2H), 5.75 (d, J=5.8Hz, 1H), 4.61 (m, 12H), 4.47 (m, 1H), 4.18 (m, 2H).
    • EXAMPLE 11A
  • A solution of EXAMPLE 6 (3.65Kg) and triethyl orthoformate (4.93L) in toluene (18.5L) at reflux was stirred for 1 hour, treated with acetic anhydride (3.50L), stirred for 12-24 hours, cooled to ambient temperature and concentrated with a toluene (8L) azeotrope until no triethyl orthoformate was detected by 1H NMR (CDCl3).
    • EXAMPLE 11B
  • A solution of EXAMPLE 4 (2.58Kg) in DMSO (6.75Kg) at 14° C. was treated with EXAMPLE 11A in DMSO (9.50Kg) over 1 hour, stirred for 15 minutes, treated with potassium carbonate (2.25Kg), stirred at 60-70° C. for 1-2 hours, cooled to 30° C., treated sequentially with acetonitrile (13.3Kg) and 9% aqueous citric acid (20.2Kg), each over 15 minutes, cooled to ambient temperature and filtered. The filtrant was washed with 9% aqueous citric acid (10 Kg)/acetonitrile (9.1L) and acetonitrile (2×9.1L) and dried at 40-45° C. to provide 4.49Kg of product. 1H NMR (DMSO-d6) δ 8.72 (s, 1H), 8.14 (dd, J=11.4, 9.6Hz, 1H), 8.03 (dd, J=11.2, 9.8Hz, 1H), 7.51 (ddd, J=12.6, 6.6, 1.2 Hz, 1H), 6.82 (br s, 2H), 4.23 (q, J=7.5Hz, 2H), 1.28 (t, J=7.5 Hz, 3H).
    • EXAMPLE 12
  • A mixture of EXAMPLE 2 (1.46Kg) and potassium bicarbonate (4.66Kg) in N-methylpyrrolidinone (36.8Kg) was stirred at 60° C. for 1 hour, treated with EXAMPLE 11B (4Kg), stirred for 3 hours, cooled to ambient temperature, treated with N,N-dimethylaminopyridine (65 g) and acetic anhydride (5.34Kg) while keeping the temperature below 45° C., stirred until the intermediate alcohol was consumed, cooled to ambient temperature, and filtered. The filtrant was washed with N-methylpyrrolidinone (4.3Kg), and the filtrate was warmed to 70° C., treated with water (40.4Kg), cooled to ambient temperature, and filtered. The filtrant was washed with water (2×12Kg) and dried under vacuum at 50° C. to provide 4.36 Kg of product. 1H NMR (DMSO-d6) δ 8.31 (d, J=0.7 Hz, 1H), 7.81 (dd, J=8.8, 9.9 Hz, 1H), 7.55 (d, J=12.9 Hz, 1H), 6.62 (br s, 2H), 5.75 (dd, J=1.5, 7.3 Hz, 1H), 5.00 (m, 1H), 4.16 (m, 2H), 4.02 (q, J=7.1 Hz, 2H), 3.77 (dd, J=3.3, 9.6 Hz, 2H), 1.87 (s, 3H), 1.07 (t, J=7.1 Hz, 3H).
    • EXAMPLE 13
  • A mixture of EXAMPLE 12 (1.97Kg) in dichloromethane (15.4Kg) at 0° C. was treated with 1,3-dimethyl-5,5-dichlorohydantoin (890 g) in dichloromethane (7.7Kg) over 2.5 hours, stirred for 2 hours, treated with 10% aqueous sodium hydrogen sulfite (10.2Kg), separated from the water layer, washed with water, filtered, and concentrated with an ethyl acetate (4.2Kg) azeotrope. The concentrate was treated with ethyl acetate (9Kg) and heptane (3.5Kg), stirred at 5° C. for 2 hours, and filtered. The filtrant was washed with 1:1 ethyl acetate/heptane (1.4Kg) and dried under vacuum to provide 1.84Kg of product. Mp 193-195° C.; 1H NMR (DMSO-d6, 300 MHz) δ 8.42 (d, J=0.7 Hz, 1H), 7.93 (dd, J=9.9, 1.1 Hz, 1H), 7.75 (d, J=13.9 Hz, 1H), 6.72 (br s, 1H), 5.11 (m, 1H), 4.73 (m, 2H), 4.32 (m, 2H), 4.22 (dd, J=14.0, 7.0 Hz, 2H), 2.07 (s, 3H), 1.26 (t, J=14.0 Hz, 3H).
  • The preceding is meant to be illustrative of this invention and not limiting. Obvious variations and changes are meant to be within the scope of this invention, as defined in the claims.

Claims (10)

We claim:
1. A process for making a compound having formula (V)
Figure US20150094475A1-20150402-C00008
or a salt thereof, wherein R4 is alkyl, comprising:
(c) reacting, at about 100° C. to about 140° C., a compound having formula (IV)
Figure US20150094475A1-20150402-C00009
and a trialkylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and a carboxylic anhydride for about 30 minutes to about 12 hours; and
(d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the compound having formula (V), mixing or not mixing the product mixture and water, and isolating or not isolating the compound having formula (V).
2. A compound having formula (V) prepared as set forth in claim 1.
3. A process according to claim 1 for making ethyl (2E/Z)-3-((6-amino -3,5 -difluoropyridin-2-yl)amino)-2-(2,4,5 -trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
(c) reacting, at about 100° C. to about 140° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and a trialkylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and a carboxylic anhydride for about 30 minutes to about 12 hours; and
(d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising ethyl (2E/Z)-3-((6-amino-3,5 -difluoropyridin-2-yl)amino)-2-(2,4,5 -trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
4. (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in claim 3.
5. A process according to claim 3 for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
(c) reacting, at about 100° C. to about 140° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and triethylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and acetic anhydride for about 30 minutes to about 12 hours; and
(d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)-amino)-2-(2,4,5-trifluorobenzoyl)-2 -propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
6. (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in claim 5.
7. A process according to claim 5 for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
(c) reacting, at about 110° C. to about 115° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and triethylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and acetic anhydride for about 30 minutes to about 12 hours; and
(d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing or not mixing the product mixture and water, and isolating or not isolating the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate.
8. (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in claim 7.
9. A process according to claim 7 for making ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, comprising:
(c) reacting, at about 110° C. to about 115° C., ethyl 3-oxo-3-(2,4,5-trifluorophenyl)propanoate and triethylorthoformate for about 30 minutes to about 2 hours and reacting the product therefrom and acetic anhydride for about 30 minutes to about 12 hours; and
(d) reacting the product of step (c) and 2,6-diamino-3,5-difluoropyridine to provide a product mixture comprising the ethyl (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, mixing the product mixture and water, and isolating the ethyl (2E/Z)-3 -((6-amino-3,5 -difluoropyridin-2-yl)amino)-2-(2,4,5 -trifluorobenzoyl)-2-propenoate.
10. (2E/Z)-3-((6-amino-3,5-difluoropyridin-2-yl)amino)-2-(2,4,5-trifluorobenzoyl)-2-propenoate, or a salt thereof, prepared as set forth in claim 9.
US14/570,098 2004-07-30 2014-12-15 Preparation of Pyridonecarboxylic Acid Antibacterials Abandoned US20150094475A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US14/570,098 US20150094475A1 (en) 2004-07-30 2014-12-15 Preparation of Pyridonecarboxylic Acid Antibacterials

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US59289304P 2004-07-30 2004-07-30
US61732704P 2004-10-08 2004-10-08
US11/191,319 US7576216B2 (en) 2004-07-30 2005-07-28 Preparation of pyridonecarboxylic acid antibacterials
US12/543,240 US8299254B2 (en) 2004-07-30 2009-08-18 Preparation of pyridonecarboxylic acid antibacterials
US13/663,601 US8648196B2 (en) 2004-07-30 2012-10-30 Preparation of pyridonecarboxylic acid antibacterials
US14/176,334 US8927723B2 (en) 2004-07-30 2014-02-10 Preparation of pyridonecarboxylic acid antibacterials
US14/570,098 US20150094475A1 (en) 2004-07-30 2014-12-15 Preparation of Pyridonecarboxylic Acid Antibacterials

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US14/176,334 Continuation US8927723B2 (en) 2004-07-30 2014-02-10 Preparation of pyridonecarboxylic acid antibacterials

Publications (1)

Publication Number Publication Date
US20150094475A1 true US20150094475A1 (en) 2015-04-02

Family

ID=36584829

Family Applications (5)

Application Number Title Priority Date Filing Date
US11/191,319 Active 2028-12-06 US7576216B2 (en) 2004-07-30 2005-07-28 Preparation of pyridonecarboxylic acid antibacterials
US12/543,240 Active 2026-02-12 US8299254B2 (en) 2004-07-30 2009-08-18 Preparation of pyridonecarboxylic acid antibacterials
US13/663,601 Active US8648196B2 (en) 2004-07-30 2012-10-30 Preparation of pyridonecarboxylic acid antibacterials
US14/176,334 Active US8927723B2 (en) 2004-07-30 2014-02-10 Preparation of pyridonecarboxylic acid antibacterials
US14/570,098 Abandoned US20150094475A1 (en) 2004-07-30 2014-12-15 Preparation of Pyridonecarboxylic Acid Antibacterials

Family Applications Before (4)

Application Number Title Priority Date Filing Date
US11/191,319 Active 2028-12-06 US7576216B2 (en) 2004-07-30 2005-07-28 Preparation of pyridonecarboxylic acid antibacterials
US12/543,240 Active 2026-02-12 US8299254B2 (en) 2004-07-30 2009-08-18 Preparation of pyridonecarboxylic acid antibacterials
US13/663,601 Active US8648196B2 (en) 2004-07-30 2012-10-30 Preparation of pyridonecarboxylic acid antibacterials
US14/176,334 Active US8927723B2 (en) 2004-07-30 2014-02-10 Preparation of pyridonecarboxylic acid antibacterials

Country Status (1)

Country Link
US (5) US7576216B2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
AR114185A1 (en) * 2018-01-23 2020-07-29 Adama Makhteshim Ltd SYNTHESIS OF 5-CHLORINE-2 - [(3,4,4-TRIFLUORO-3-BUTEN-1-IL) THIO] -THAZOLE

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5221575B2 (en) * 1972-03-18 1977-06-11
DE3420743A1 (en) * 1984-06-04 1985-12-05 Bayer Ag, 5090 Leverkusen 7-AMINO-1-CYCLOPROPYL-6,8-DIHALOGEN-1,4-DIHYDRO-4-OXO-3-CHINOLINE CARBONIC ACIDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR CONTAINING ANTIBACTERIAL AGENTS
US4696814A (en) * 1985-08-21 1987-09-29 Warner-Lambert Company Parenteral phenytoin compositions
IT1207994B (en) * 1986-01-03 1989-06-01 Therapicon Srl WATER SOLUBLE SALTS OF ANTI-INFLAMMATORY AND ANALGESIC ADAPTITY COMPOUNDS, THEIR PREPARATION AND USE IN PHARMACEUTICAL COMPOSITIONS.
DE3626868A1 (en) 1986-08-08 1988-02-11 Bayer Ag PARENTERAL SOLUTION
EP0339406A1 (en) 1988-04-19 1989-11-02 Hokuriku Pharmaceutical Co.,Ltd Quinoline-3-carboxylic acid derivatives, process for preparing the same, and composition exhibiting excellent antibacterial effect containing the same
AU6001790A (en) 1989-08-02 1991-02-07 Warner-Lambert Company Formulations of phenytoin sodium for intravenous administration
JP2613139B2 (en) * 1990-07-19 1997-05-21 エスエス製薬 株式会社 Quinolonecarboxylic acid derivatives
DE69330392T2 (en) * 1992-04-03 2001-11-08 Nippon Kayaku Kk Hard capsule containing Cytarabine Ocfosfate
US5578609A (en) 1994-03-25 1996-11-26 The Dupont Merck Pharmaceutical Company 2-carbocyclic and 2-heterocyclic quinoline-4-carboxylic acids and salts thereof useful as immunosuppressive agents
TW487582B (en) 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
CA2290712C (en) 1995-09-22 2003-09-09 Wakunaga Pharmaceutical Co., Ltd. Novel pyridonecarboxylic acid derivatives or their salts, and antibacterial agents containing the same as their effective components
JPH11292873A (en) 1998-04-07 1999-10-26 Dainippon Pharmaceut Co Ltd Production of quinolonecarboxylic acid derivative and intermediate thereof
JP2001002648A (en) 1999-06-17 2001-01-09 Kikkoman Corp N-substituted azepan derivative and salt thereof
JP3477466B2 (en) 1999-09-02 2003-12-10 湧永製薬株式会社 Quinolinecarboxylic acid derivatives or salts thereof
ATE329579T1 (en) 1999-11-12 2006-07-15 Abbott Lab SOLID DISPERSION WITH RITONAVIR, FENOFIBRATE OR GRISEOFULVIN
GB9929037D0 (en) * 1999-12-08 2000-02-02 Glaxo Wellcome Spa Heterocyclic derivatives
CN1440393A (en) 2000-04-28 2003-09-03 田边制药株式会社 Cyclic compounds
FR2827281B1 (en) 2001-07-16 2003-12-19 Sanofi Synthelabo PROCESS FOR THE PREPARATION OF 4-METHYLAMINO-4-PHENYLPIPERIDINE
JP4290381B2 (en) 2002-04-11 2009-07-01 学校法人 聖マリアンナ医科大学 Emulsion containing pyridonecarboxylic acid compound
WO2004073654A2 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained supression of gastric acid
US7576216B2 (en) * 2004-07-30 2009-08-18 Abbott Laboratories Preparation of pyridonecarboxylic acid antibacterials
LT3056492T (en) * 2004-10-08 2022-01-25 Abbvie Inc. Meglumine salt and crystalline forms thereof of a drug (delafloxacin)
US8497378B2 (en) * 2008-09-24 2013-07-30 Rib-X Pharmaceuticals, Inc. Process for making quinolone compounds

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Liu, abstract only CA136:325403, Yaoxue Xuebao, 2001, 36(6), 419-422. *
Wang, abstract only CA 140:199182, Huaxue Fanying Gongcheng Yu Gongyi, 2003, 19(3), 237-241. *
Wang, abstract only CA 141:106352, Huaxue Shiji, 2004, 26(1), 47-49. *
Wang, abstract only CA 141:173943, Huaxue Fanying Gongcheng Yu Gongyi, 2004, 20(1), 75-79. *
Yoon, J Heterocyclic Chem, Vol 34, pp 1021-1027, 1997. *

Also Published As

Publication number Publication date
US8927723B2 (en) 2015-01-06
US7576216B2 (en) 2009-08-18
US20100041890A1 (en) 2010-02-18
US20140155610A1 (en) 2014-06-05
US8299254B2 (en) 2012-10-30
US20130085281A1 (en) 2013-04-04
US8648196B2 (en) 2014-02-11
US20060128686A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
EP2100892B1 (en) Preparation of pyridonecarboxylic acid antibacterials
DE69925150T2 (en) Naphthyridine compounds and their azaisostereren analogues as antibacterial agents
AU779550B2 (en) Nitrogen-containing heterocyclic compounds and benamide compounds and drugs containing the same
JPS6327471A (en) Production of optically active benzenesulfonamide derivative
HU194548B (en) Process for producing new phenyl-acetic acid derivatives
KR101420892B1 (en) Process for the preparation of Imatinib and intermediates thereof
JP3269574B2 (en) Methananoanthracene compounds, pharmaceutical compositions containing the same for treating neuropsychiatric disorders, and methods and intermediates for producing the compounds
US20150094475A1 (en) Preparation of Pyridonecarboxylic Acid Antibacterials
EP1455790B1 (en) Use of pyridine-2,4-dicarboxylic acid diamides and of pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
NO178660B (en) Analogous process for the preparation of N-aryl-piperazine alkanamide compounds
ZA200408213B (en) Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the sythesis of biologically active piperazines
US5064963A (en) Process for the synthesis of n-(3-(1h-imidazol-1-yl)phenyl-4-(substituted)-2-pyrimidinamines
AU2005307447B2 (en) Novel pyridonecarboxylic acid derivatives or salts thereof
JPH03135941A (en) A number of glyoxylcyclohexenedion compound
HU193930B (en) Process for preparing 6-(aminomethyl)-penicillanic acid-1,1-dioxide esters
US5719293A (en) Intermediate for preparing a pharmaceutically active compound
JPH10231288A (en) Production of 2-chloro-4-aminomethylpyridine
JP2008502675A (en) 1β-methylcarbapenem derivative and method for producing the same
HUT74676A (en) Vasoconstrictive substituted dihydropyranopyridines, process for producing them and pharmaceutical compositions containing them
US4900742A (en) N-(pyrrol-1-yl)pyridinamine compounds having memory enhancing properties
KR20050020083A (en) New derivatives of 5-aminomethyloxazoline-2-one containing piperidine and preparation methods
EP2692725A1 (en) Method for producing phenoxypyridine derivative
JPH1077270A (en) 2-(1-chlorovinyl)pyridine derivative and its production
JPH11322706A (en) New amino acid derivative and its production

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION